Loading...
Market
How many patients will be treated with TECELRA by the end of 2024?
2
Resolution / Starting Odds
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Official reports from Adaptimmune or healthcare industry publications
Story
FDA Grants Accelerated Approval to Adaptimmune's TECELRA, First Engineered Cell Therapy for Solid Tumor
Aug 2, 2024, 09:45 AM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Adaptimmune's TECELRA® (afamitresgene autoleucel), marking the first approved engineered cell therapy for a solid tumor. This gene therapy is indicated for the treatment of adults with unresectable or metastatic synovial sarcoma, a rare form of cancer that develops in the soft tissues of the body. The approval represents a significant milestone for the oncology community, extending the power of immunotherapies into difficult-to-reach sarcomas. Patients eligible for this treatment must have tumors expressing MAGE-A4 and be positive for HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P.
View original story
Similar markets
Advanced Synovial Sarcoma • 25%
Other Sarcomas • 25%
Other Solid Tumors • 25%
Combination Therapies • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10,000 • 25%
10,000 to 20,000 • 25%
20,001 to 30,000 • 25%
More than 30,000 • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
Less than 5,000 • 25%
5,000 - 10,000 • 25%
10,000 - 15,000 • 25%
More than 15,000 • 25%
Less than 100 • 25%
100 to 500 • 25%
500 to 1000 • 25%
More than 1000 • 25%
Less than 100 • 25%
100 to 200 • 25%
201 to 300 • 25%
More than 300 • 25%
Less than 100 patients • 25%
100 to 500 patients • 25%
501 to 1000 patients • 25%
More than 1000 patients • 25%
Less than 100 • 33%
100 to 500 • 34%
More than 500 • 33%
Less than 50,000 • 25%
50,000 to 75,000 • 25%
75,000 to 100,000 • 25%
More than 100,000 • 25%